These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 39187850)

  • 1. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.
    Xia X; Yang Z; Lu Q; Liu Z; Wang L; Du J; Li Y; Yang DH; Wu S
    Mol Cancer; 2024 Aug; 23(1):175. PubMed ID: 39187850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond.
    Zhou Z; Wang J; Wang J; Yang S; Wang R; Zhang G; Li Z; Shi R; Wang Z; Lu Q
    Mol Cancer; 2024 Jun; 23(1):131. PubMed ID: 38918817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
    Yuan G; Ye M; Zhang Y; Zeng X
    Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
    Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
    Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
    Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.
    Spiga M; Martini E; Maffia MC; Ciceri F; Ruggiero E; Potenza A; Bonini C
    Semin Immunopathol; 2024 Jul; 46(3-4):8. PubMed ID: 39060547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomaterials Boost CAR-T Therapy for Solid Tumors.
    Long J; Wang Y; Jiang X; Ge J; Chen M; Zheng B; Wang R; Wang M; Xu M; Ke Q; Wang J
    Adv Healthc Mater; 2024 Aug; 13(20):e2304615. PubMed ID: 38483400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating tumor physical microenvironment for fueling CAR-T cell therapy.
    Luo Z; Yao X; Li M; Fang D; Fei Y; Cheng Z; Xu Y; Zhu B
    Adv Drug Deliv Rev; 2022 Jun; 185():114301. PubMed ID: 35439570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
    Wagner J; Wickman E; DeRenzo C; Gottschalk S
    Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
    Pellegrino M; Del Bufalo F; De Angelis B; Quintarelli C; Caruana I; de Billy E
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
    Chen K; Liu ML; Wang JC; Fang S
    Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.